Brian Behm headshot
BB

Brian W. Behm

Associate Professor
Unit: School of Medicine
Department: Department of Medicine, Gastroenterology
Office location and address
Digestive Health Center
1335 Lee St
Charlottesville, Virginia 22903
Education
MD, Medicine, University of Virginia
Fellowship, Gastroenterology, University of Virginia
Residency, Internal Medicine, University of California San Francisco
BA, Cornell University
Biography

Dr. Brian Behm is a gastroenterologist focused on treating patients with inflammatory bowel disease (IBD). He is an associate professor of medicine and is board certified in gastroenterology. 

Dr. Behm was born in northeast Ohio. He completed his undergraduate studies at Cornell University, graduating with distinction. He earned his medical degree at the University of Virginia, then completed an internal medicine residency at the University of California, San Francisco. He returned to UVA for his gastroenterology fellowship, then joined the UVA faculty in 2006. He went on to earn a master’s degree in health evaluation sciences from UVA in 2007.

Along with other services, Dr. Behm treats microscopic colitis, pouchitis and indeterminate colitis.

Dr. Behm lives in Charlottesville and enjoys hiking, bicycling and kayaking.

ECOSPOR IV: AN OPEN-LABEL EXTENSION OF STUDY SERES-012 EVALUATING SER-109 IN ADULT SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI)
Source: Seres Therapeutics, Inc.
November 07, 2017 – November 06, 2022
ENTYVIO Outcomes in Real-World Bio-naive UC and Crohn's Disease Patients (EVOLVE)-USA
Source: PPD Investigator Services, LLC
April 18, 2018 – April 17, 2021
Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy
Source: Centocor Research & Development, Inc.
October 28, 2011 – October 30, 2019
Continuing Education QI Initiative; The nurse's role in the management and documentation of quality measures as they deliver care for adult patients with Inflammatory Bowel Disease (IBD)
Source: MCM Education
August 01, 2016 – December 31, 2018
MD-INMD-GI A Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately Responded to or are intolerant to Anti-TNF Therapy
Source: AbbVie Inc.
June 01, 2015 – June 30, 2018
MD-INMD An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn's Disease Previously Enrolled in the Etrolizumav Phase III Protocol GA29144
Source: Genentech, Inc
July 15, 2015 – June 23, 2017
Multicenter Study Evaluating Efficacy & Safety of SAR339658 in Patients
Source: Sanofi US Service Inc.
December 13, 2012 – April 07, 2017
MD-INMD Protocol Number: RP1208 A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification For the Management of Inflammatory Bowel Disease
Source: Robarts Clinical Trials, Inc.
July 28, 2014 – April 07, 2017
MD-DHCR 213-Abbott A 5-year Registry Study of Humira (Adalimumab) in Subjects with Moderately to Severely Active Crohn's Disease (CD)
Source: Abbott Labs.
November 09, 2007 – November 08, 2016
Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab
Source: Millennium Pharmaceuticals, Inc.
March 04, 2011 – March 03, 2015
Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induciton Therapy
Source: Centocor Research & Development, Inc.
October 28, 2011 – October 30, 2014
MD-INMD REMICADECRD3001: Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at an Increased RIsk of Recurrance (PREVENT)
Source: Centocor Research & Development, Inc.
January 26, 2011 – July 30, 2014